WO2000037063A3 - Triazineone compounds for treating diseases due to sarcosystis, neospora and toxoplasma - Google Patents

Triazineone compounds for treating diseases due to sarcosystis, neospora and toxoplasma Download PDF

Info

Publication number
WO2000037063A3
WO2000037063A3 PCT/US1999/030281 US9930281W WO0037063A3 WO 2000037063 A3 WO2000037063 A3 WO 2000037063A3 US 9930281 W US9930281 W US 9930281W WO 0037063 A3 WO0037063 A3 WO 0037063A3
Authority
WO
WIPO (PCT)
Prior art keywords
sarcosystis
neospora
toxoplasma
treating diseases
diseases due
Prior art date
Application number
PCT/US1999/030281
Other languages
French (fr)
Other versions
WO2000037063A2 (en
Inventor
Thomas J Kennedy
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to DE69926794T priority Critical patent/DE69926794T2/en
Application filed by Bayer Ag filed Critical Bayer Ag
Priority to HU0104595A priority patent/HUP0104595A3/en
Priority to AU24817/00A priority patent/AU764608B2/en
Priority to BR9916391-8A priority patent/BR9916391A/en
Priority to AT99968140T priority patent/ATE302011T1/en
Priority to DK99968140T priority patent/DK1140103T3/en
Priority to EP99968140A priority patent/EP1140103B1/en
Priority to JP2000589174A priority patent/JP2002532544A/en
Priority to CA002355825A priority patent/CA2355825C/en
Priority to NZ512477A priority patent/NZ512477A/en
Publication of WO2000037063A2 publication Critical patent/WO2000037063A2/en
Publication of WO2000037063A3 publication Critical patent/WO2000037063A3/en
Priority to HK02106846.1A priority patent/HK1045266B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis

Abstract

Disclosed herein are methods of treating therapeutically, or metaphylactically infected animals susceptible to, or infected animal suffering from parasitic neurologic or abortigenic diseases such as Sarcocystidiae or Toxoplasmosis that are treatable with triazineone compound by administering thereto a pharmaceutically effective amount of ponazuril, including a single high dose therapeutic treatment.
PCT/US1999/030281 1998-12-22 1999-12-18 Triazineone compounds for treating diseases due to sarcosystis, neospora and toxoplasma WO2000037063A2 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
DK99968140T DK1140103T3 (en) 1998-12-22 1999-12-18 Ponazuril for the treatment of neurological and abortion-causing diseases caused by Coccidia
HU0104595A HUP0104595A3 (en) 1998-12-22 1999-12-18 Triazineone compounds for treating diseases due to sarcosystis, neospora and toxoplasma
AU24817/00A AU764608B2 (en) 1998-12-22 1999-12-18 Triazineone compounds for treating diseases due to sarcosystis, neospora and toxoplasma
BR9916391-8A BR9916391A (en) 1998-12-22 1999-12-18 Triazineone compounds for the treatment of diseases caused by sarcosiste, neopora and toxoplasma
AT99968140T ATE302011T1 (en) 1998-12-22 1999-12-18 PONAZURIL FOR THE TREATMENT OF DISEASES CAUSED BY COCCIDIA NEUROLOGICAL AND ABORTIGENICS
DE69926794T DE69926794T2 (en) 1998-12-22 1999-12-18 PONAZURIL FOR THE TREATMENT OF DISORDERS CAUSED BY COCCIDIA NEUROLOGICAL AND "ABORTIGENIC"
EP99968140A EP1140103B1 (en) 1998-12-22 1999-12-18 Ponazuril for treating neurologic and abortigenic diseases caused by coccidia.
NZ512477A NZ512477A (en) 1998-12-22 1999-12-18 Triazineone compounds for treating diseases due to sarcosystis, neospora and toxoplasma
CA002355825A CA2355825C (en) 1998-12-22 1999-12-18 Triazineone compounds for treating diseases due to sarcocystis, neospora and toxoplasma
JP2000589174A JP2002532544A (en) 1998-12-22 1999-12-18 Triazine-on compounds for treating diseases caused by sarcocystis, neospora and toxoplasma
HK02106846.1A HK1045266B (en) 1998-12-22 2002-09-19 Triazineone compounds for treating diseases due to sarcosystis, neospora and toxoplasma

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/218,323 1998-12-22
US09/218,323 US6150361A (en) 1998-12-22 1998-12-22 Triazineone compounds for treating diseases due to sarcosystis, neospora and toxoplasma

Publications (2)

Publication Number Publication Date
WO2000037063A2 WO2000037063A2 (en) 2000-06-29
WO2000037063A3 true WO2000037063A3 (en) 2000-10-19

Family

ID=22814646

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/030281 WO2000037063A2 (en) 1998-12-22 1999-12-18 Triazineone compounds for treating diseases due to sarcosystis, neospora and toxoplasma

Country Status (17)

Country Link
US (1) US6150361A (en)
EP (1) EP1140103B1 (en)
JP (1) JP2002532544A (en)
KR (1) KR100661111B1 (en)
CN (1) CN1221265C (en)
AT (1) ATE302011T1 (en)
AU (1) AU764608B2 (en)
BR (1) BR9916391A (en)
CA (1) CA2355825C (en)
DE (1) DE69926794T2 (en)
DK (1) DK1140103T3 (en)
ES (1) ES2247863T3 (en)
HK (1) HK1045266B (en)
HU (1) HUP0104595A3 (en)
NZ (1) NZ512477A (en)
WO (1) WO2000037063A2 (en)
ZA (1) ZA200103920B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU766542B2 (en) * 1998-10-08 2003-10-16 New Ace Research Company Novel compositions and methods for prevention and treatment of protozoal disease
DE19958388A1 (en) * 1999-12-03 2001-06-07 Bayer Ag Triazinone compounds for the treatment of infestations with parasitic protozoa-related diseases
BR0110232A (en) * 2000-04-25 2003-01-21 Wyeth Corp Protozoan equine myencephalitis vaccine
DE10040174A1 (en) * 2000-08-17 2002-02-28 Bayer Ag Treatment of coccidiosis comprises administration of haloalkylsulfonyl substituted phenoxyphenyl-triazinetrione derivatives
DE102004001558A1 (en) * 2004-01-10 2005-08-18 Bayer Healthcare Ag Medicinal products for topical application in animals
DE102006038292A1 (en) * 2006-08-16 2008-02-21 Bayer Healthcare Ag Transdermal use of triazines to combat coccidial infections
DE102007025908A1 (en) 2007-06-01 2008-12-04 Bayer Healthcare Ag Formulations containing triazinones and iron
DE102009012423A1 (en) * 2009-03-10 2010-09-16 Bayer Animal Health Gmbh Preparation based on oil

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4219552A (en) * 1977-04-27 1980-08-26 Bayer Aktiengesellschaft 1-(4-Phenoxy-phenyl)-1,3,5-triazines, their use as growth promoters
WO1998043644A1 (en) * 1997-03-31 1998-10-08 David Granstrom Formulations and methods to treat and prevent equine protozoal myeloencephalitis
DE19824483A1 (en) * 1998-06-02 1999-12-09 Bayer Ag Semi-solid aqueous preparations for oral application of toltrazuril sulfone
WO2000019964A2 (en) * 1998-10-08 2000-04-13 New Ace Research Company Novel compositions and methods for prevention and treatment of protozoal disease

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4933341A (en) * 1988-10-08 1990-06-12 Bayer Aktiengesellschaft Substituted 1,3,5-triazinetriones, for use against parasitic protozoa
US5883095A (en) * 1997-08-07 1999-03-16 University Of Kentucky Research Foundation Formulations and methods to treat and prevent equine protozoal myeloencephalitis

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4219552A (en) * 1977-04-27 1980-08-26 Bayer Aktiengesellschaft 1-(4-Phenoxy-phenyl)-1,3,5-triazines, their use as growth promoters
WO1998043644A1 (en) * 1997-03-31 1998-10-08 David Granstrom Formulations and methods to treat and prevent equine protozoal myeloencephalitis
DE19824483A1 (en) * 1998-06-02 1999-12-09 Bayer Ag Semi-solid aqueous preparations for oral application of toltrazuril sulfone
WO2000019964A2 (en) * 1998-10-08 2000-04-13 New Ace Research Company Novel compositions and methods for prevention and treatment of protozoal disease

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KRAMPITZ H E ET AL: "EXPERIMENTAL TREATMENT OF HEPATOZOON INFECTIONS WITH THE ANTICOCCIDIAL AGENT TOLTRAZURIL", JOURNAL OF VETERINARY MEDICINE. SERIES B - ZENTRALBLATT FUER VETERINAERMEDIZIN. REINE B,DE,PAUL PAREY, BERLIN, vol. 35, no. 2, 1988, pages 131 - 137, XP000882187, ISSN: 0931-1793 *
LINDSAY D S ET AL: "Examination of the activities of 43 chemotherapeutic agents against Neospora caninum tachyzoites in cultured cells", AMERICAN JOURNAL OF VETERINARY RESEARCH,XX,XX, vol. 55, no. 7, July 1994 (1994-07-01), pages 976 - 981-981, XP002101367, ISSN: 0002-9645 *

Also Published As

Publication number Publication date
KR100661111B1 (en) 2006-12-26
CA2355825C (en) 2008-07-08
DK1140103T3 (en) 2005-12-19
CN1342081A (en) 2002-03-27
ES2247863T3 (en) 2006-03-01
AU2481700A (en) 2000-07-12
AU764608B2 (en) 2003-08-28
EP1140103A2 (en) 2001-10-10
US6150361A (en) 2000-11-21
HUP0104595A2 (en) 2002-04-29
JP2002532544A (en) 2002-10-02
CA2355825A1 (en) 2000-06-29
EP1140103B1 (en) 2005-08-17
CN1221265C (en) 2005-10-05
DE69926794D1 (en) 2005-09-22
ZA200103920B (en) 2002-05-15
ATE302011T1 (en) 2005-09-15
BR9916391A (en) 2001-09-18
NZ512477A (en) 2004-05-28
HUP0104595A3 (en) 2003-10-28
HK1045266A1 (en) 2002-11-22
DE69926794T2 (en) 2006-01-19
KR20010080570A (en) 2001-08-22
WO2000037063A2 (en) 2000-06-29
HK1045266B (en) 2006-07-07

Similar Documents

Publication Publication Date Title
WO2000037064A3 (en) Triazineone compounds for treating diseases due to sarcosystis, neospora and toxoplasma
WO2005002572A3 (en) Use of [3.2.0] heterocyclic compounds and analogs thereof for the treatment of cancer, inflammation and infectious diseases
MXPA04004966A (en) 3-beta-D-RIBOFURANOSYLTHIAZOLO[4,5-d.
HRP20080492T3 (en) Phenyl-carboxamide compounds useful for treating pain
MY119375A (en) Treatment of tinnitus using neuroprotective agents
WO2003005960A3 (en) Novel bicyclic and tricyclic cannabinoids
GB0130677D0 (en) Medicaments and novel compounds
WO2000037063A3 (en) Triazineone compounds for treating diseases due to sarcosystis, neospora and toxoplasma
EA199800717A1 (en) METHOD FOR THE TREATMENT OF MAMMAL DISEASES AND THE CYVITTERION COMPOSITION
HK1024424A1 (en) Methods of therapeutic administration of anti-cd40l compounds
BR9916417A (en) Triazineone compounds for the treatment of diseases due to sarcosystis, neospora and toxoplasma
CA2289017A1 (en) The use of a nitroxide or a prodrug thereof in the prophylactic and therapeutic treatment of cancer
EP1050303A3 (en) Methods and compositions for treating age-related behavioral disorders in companion animals
CA2409926A1 (en) Praziquantel compounds for treating diseases due to sarcocystis, neospora, toxoplasma and isospora
WO2001007029A3 (en) Substituted guanidines and the use thereof
ATE248607T1 (en) AMINOTETRALIN DERIVATIVES FOR THE THERAPY OF CARDIOVASCULAR DISEASES
EA200200846A1 (en) CONNECTIONS USEFUL FOR THE TREATMENT OR PREVENTION OF DISEASES MEDIATED BY ALPHA-2B-ADRENOCEPTOR
HUP9800835A3 (en) Pharmaceutical composition for treatment of diseases of honey-bees caused by ascophaera apis
US5721216A (en) Treatment of diseases caused by parasitic protozoa and fungal diseases by administration of 5-deoxy-5-(substituted) ethylthioribose compounds
MX9605153A (en) Pharmaceutical agents for the treatment of acute and chronic inflammatory diseases.

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 99814834.2

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 1999968140

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2001/03920

Country of ref document: ZA

Ref document number: 200103920

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 1020017006549

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2355825

Country of ref document: CA

Ref document number: 2355825

Country of ref document: CA

Kind code of ref document: A

Ref document number: 2000 589174

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 512477

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/006437

Country of ref document: MX

Ref document number: 24817/00

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 1020017006549

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 1999968140

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 24817/00

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 1999968140

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1020017006549

Country of ref document: KR